Cancer Medicine, 2022 Background Maintenance therapy with proteasome inhibitors (PIs) can improve outcomes of multiple myeloma (MM) patients, however, the neurotoxicity and parenteral route of bortezomib limit its long‐term use.
Man Shen +8 more
doaj +1 more source
Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation
Blood Cancer Journal, 2021 MYC upregulation is associated with multidrug refractory disease in patients with multiple myeloma (MM). We, isolated patient-derived MM cells with high MYC expression and discovered that NCOR2 was down-regulated in these cells.
Tomoaki Mori +13 more
doaj +1 more source
Incidence and Risk Factors of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients Having Undergone Autologous Stem Cell Transplantation [PDF]
, 2012 Background: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication of bisphosphonate therapy. Due to their long survival and subsequently high cumulative doses of bisphosphonates, multiple myeloma patients have the highest risk ...
Baumann, Philipp +9 more
core +1 more source
Multiple myeloma and physical activity: a scoping review [PDF]
, 2015 Objectives: Multiple myeloma is the second most common haematological cancer. A growing body of literature is emerging that investigates the role physical activity plays in all stages of multiple myeloma (prevention and survivorship) and to date no ...
Fisher, A +6 more
core +1 more source
Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway
Protein & Cell, 2018 Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of
Li Yang +13 more
doaj +1 more source
Selinexor: Targeting a novel pathway in multiple myeloma
eJHaem, 2023 Selinexor is an orally bioavailable selective inhibitor of nuclear export compound that inhibits exportin‐1 (XPO1), a novel therapeutic target that is overexpressed in multiple myeloma (MM) and is responsible for the transport of ∼220 nuclear proteins to
Clifton C. Mo +9 more
doaj +1 more source
A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease: Modelling Therapies for Multiple Myeloma Induced Bone Disease [PDF]
, 2015 Multiple myeloma bone disease is devastating for patients and a major cause of morbidity. The disease leads to bone destruction by inhibiting osteoblast activity while stimulating osteoclast activity.
Fagan, Michael J. +2 more
core +2 more sources
Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma [PDF]
, 2012 Copyright @ 2013 Macmillan Publishers Limited. This is the author's accepted manuscript. The final published article is available from the link below.Regulation of cell survival is a key part of the pathogenesis of multiple myeloma (MM).
A Barbarulo +63 more
core +2 more sources
Clinical and Applied Thrombosis/Hemostasis, 2023 Venous thromboembolism (VTE) is a serious complication commonly experienced in cancer patients. Incidence of VTE typically brings poor prognosis as it represents the second most common cause of mortality in cancer patients just after the malignancy ...
Hussein Awada MD +9 more
doaj +1 more source
Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
Cells, 2022 Multiple Myeloma (MM) is a hematologic malignancy characterized by the proliferation of monoclonal plasma cells localized within the bone marrow. Bone disease with associated osteolytic lesions is a hallmark of MM and develops in the majority of MM ...
Zachary S. Bernstein +2 more
doaj +1 more source